Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun;111(6):1197-1198.
doi: 10.1002/cpt.2580. Epub 2022 Mar 31.

Response to "Lorlatinib Exposed: A Far from Optimal Dose"

Joseph Chen  1 , Ana Ruiz-Garcia  1 , Leonard P James  1 , Gerson Peltz  1 , Holger Thurm  1 , Jill Clancy  1 , Jennifer Hibma  1
Affiliations
Comment

Response to "Lorlatinib Exposed: A Far from Optimal Dose"

Joseph Chen et al. Clin Pharmacol Ther. 2022 Jun.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Shaw, A.T. et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 18, 1590-1599 (2017).
    1. Chen, J., Houk, B., Pithavala, Y.K. & Ruiz-Garcia, A. Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants. CPT Pharmacometrics Syst. Pharmacol. 10, 148-160 (2021).
    1. Chen, J. et al. Lorlatinib exposure-response analyses for safety and efficacy in a phase I/II trial to support benefit-risk assessment in non-small cell lung cancer. Clin. Pharmacol. Ther. 110, 1273-1281 (2021).

LinkOut - more resources